Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 10/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 3/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315223 | 1.00 | BRD4 (0.41) | BRD4CREBBPCYP2C19CYP1A2CYP2C9 | |
| SCHEMBL2414199 | 0.86 | BRD4 (0.35) | BRD4CREBBPCYP2C19CYP1A2CYP2C9 | |
| SCHEMBL2414203 | 0.86 | BRD4 (0.35) | BRD4CREBBPCYP2C19CYP1A2CYP2C9 | |
| SCHEMBL314386 | 0.79 | BRD4 (0.37) | BRD4CREBBPMAPK1 | |
| SCHEMBL314387 | 0.79 | BRD4 (0.37) | BRD4CREBBPMAPK1 | |
| SCHEMBL316245 | 0.79 | MKNK1 (0.39) | — | |
| SCHEMBL316246 | 0.79 | MKNK1 (0.39) | — | |
| SCHEMBL314383 | 0.77 | — | — | |
| SCHEMBL314382 | 0.77 | — | — | |
| SCHEMBL2142139 | 0.76 | CHRNB1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093394-B2 | Derivatives of 5-thioxylopyranose and use of same for treatment | LABORATOIRES FOURNIER S.A. (FR) | 2012-01-10 | — | — | US | disclosed |
| EP-2066683-B1 | DERIVATIVES OF 5-THIOXYLOPYRANOSE AND USE OF SAME FOR TREATMENT | FOURNIER LAB SA (FR) | 2010-11-03 | — | — | EP | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | BRD4 3810/4885CREBBP 4455/4885CYP2C19 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.